KCTBASE

Low Hepatic Toxicity in Primary and Metastatic Liver Cancers after Stereotactic Ablative Radiotherapy Using 3 Fractions

Journal of Korean Medical Science 2015년 30권 8호 p.1055 ~ p.1061

배선현(Bae Sun-Hyun) - Soonchunhyang University College of Medicine Department of Radiation Oncology
김미숙(Kim Mi-Sook) - Korea Institute of Radiological and Medical Sciences Department of Radiation Oncology
장원일(Jang Won-Il) - Korea Institute of Radiological & Medical Sciences Department of Radiation Oncology
조철구(Cho Chul-Koo) - Korea Institute of Radiological & Medical Sciences Department of Radiation Oncology
유형준(Yoo Hyung-Jun) - Korea Institute of Radiological & Medical Sciences Department of Radiation Oncology
김금배(Kim Kum-Bae) - Korea Institute of Radiological & Medical Sciences Department of Radiation Oncology
한철주(Han Chul-Ju) - Korea Institute of Radiological & Medical Sciences Department of Internal Medicine
박수철(Park Su-Cheol) - Korea Institute of Radiological and Medical Sciences Korea Cancer Center Hospital Department of Internal Medicine
이동한(Lee Dong-Han) - Korea Institute of Radiological and Medical Sciences CyberKnife Center

Abstract

This study evaluated the incidence of hepatic toxicity after stereotactic ablative radiotherapy (SABR) using 3 fractions to the liver, and identified the predictors for hepatic toxicity. We retrospectively reviewed 78 patients with primary and metastatic liver cancers, who underwent SABR using 3 fractions between 2003 and 2011. To examine the incidence of hepatic toxicity, we defined newly developed hepatic toxicity≥grade 2 according to the National Cancer Institute Common Terminology Criteria for Adverse Events v4.0 within 3 months after the end of SABR as a significant adverse event. To identify the predictors for hepatic toxicity, we analyzed several clinical and dosimetric parameters (rV5Gy-rV35Gy: normal liver volume receiving